The first and only liquid
non-stimulant ADHD therapy

onyda xr arc

Easy to take

  • ONYDA XR (clonidine HCI) is dosed once daily at bedtime, with or without food1
  • ONYDA XR is available in concentration of 0.1 mg/mL
onyda xr medication dosing chart
  • Orange-flavored oral suspension only requires gentle shaking (to avoid foaming) before taking. Use the included dispenser.
onyda xr medication dosing bottle

Available in bottles containing 30 mL and 60 mL.

Easy to titrate

Initiation Starting dose
Starting dosage is 0.1 mg of ONYDA XR orally.
If switching from another clonidine product, discontinue and titrate ONYDA XR using recommended schedule1
Titration
Titrate in increments of 0.1 mg per day at weekly intervals depending on clinical response up to a maximum dosage of 0.4 mg per day*1
*See relevant warnings and precautions in the important safety information
Discontinuation
Taper in decrements of no more than 0.1 mg every 3 to 7 days to avoid rebound hypertension1

Dosing & Titration Calculator

Use the calculator below to see the prescription and bottle size for your dosing schedule.*

*Recommended starting dose is 0.1 mg daily at bedtime. Titrate the dose of ONYDA XR in increments of 0.1 mg per day at weekly intervals depending on clinical response up to the maximum recommended dosage of 0.4 mg once daily at bedtime. When discontinuing, taper in decrements of no more than 0.1 mg every 3 to 7 days to avoid rebound hypertension.1 Monitor vital signs frequently in patient. See relevant warnings and precautions in the important safety information.

ADHD, Attention Deficit Hyperactivity Disorder

REFERENCES: 1. ONYDA XR [package insert]. Tris Pharma, Inc., Monmouth Junction, NJ.

Back to Top arrow up
IMPORTANT SAFETY INFORMATION

ONYDA™ XR (clonidine HCI) is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older.

See Additional Important Safety Information.

INDICATION

ONYDA™ XR (clonidine HCI) is a centrally acting alpha2-adrenergic agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older.

IMPORTANT SAFETY INFORMATION

Contraindications:

ONYDA XR is contraindicated in patients with history of a hypersensitivity reaction to clonidine.

Warnings & Precautions:

Adverse Reactions:

Clinically Important Drug Interactions:

Use in Specific Populations:

To report SUSPECTED ADVERSE REACTIONS, contact Tris Pharma, Inc. at 1-732-940-0358 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see ONYDA XR PI for Full Prescribing Information.

You are now leaving this website

You are about to leave ONYDAhcp.com and enter a website operated by a third party. Would you like to continue?

Yes
×
Interested in more information?

To learn more about Tris ADHD products, or to speak to a representative, please click below.

Request Info
up arrowTop